Christian P Larsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/752765/publications.pdf

Version: 2024-02-01

231 papers

22,435 citations

9756 73 h-index 145 g-index

238 all docs

238 docs citations

times ranked

238

14546 citing authors

#	Article	IF	Citations
1	hlaR: A rapid and reproducible tool to identify eplet mismatches between transplant donors and recipients. Human Immunology, 2022, 83, 248-255.	1.2	5
2	Great Expectations. American Journal of Transplantation, 2022, , .	2.6	0
3	Longitudinal Evaluation of Cytopenias in the Renal Transplant Population. Transplantation Direct, 2022, 8, e1339.	0.8	1
4	CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. American Journal of Transplantation, 2021, 21, 208-221.	2.6	42
5	Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. American Journal of Transplantation, 2021, 21, 1691-1698.	2.6	18
6	Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial. American Journal of Transplantation, 2021, 21, 3066-3076.	2.6	11
7	CMV Status Drives Distinct Trajectories of CD4+ T Cell Differentiation. Frontiers in Immunology, 2021, 12, 620386.	2.2	15
8	Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. Journal of Clinical Microbiology, 2021, , JCM0016121.	1.8	7
9	Implications of defective immune responses in SARS-CoV-2–vaccinated organ transplant recipients. Science Immunology, 2021, 6, .	5.6	16
10	Belatacept Conversion in Kidney After Liver Transplantation. Transplantation Direct, 2021, 7, e780.	0.8	5
11	Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States. Clinical Transplantation, 2021, , e14531.	0.8	8
12	The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients. American Journal of Transplantation, 2020, 20, 573-581.	2.6	19
13	Avoidance of CNI and steroids using belatacept—Results of the Clinical Trials in Organ Transplantation 16 trial. American Journal of Transplantation, 2020, 20, 3599-3608.	2.6	16
14	CD45RB Status of CD8+ T Cell Memory Defines T Cell Receptor Affinity and Persistence. Cell Reports, 2020, 30, 1282-1291.e5.	2.9	17
15	Managing COVID-19-positive Solid Organ Transplant Recipients in the Community: What a Community Healthcare Provider Needs to Know. Transplantation Direct, 2020, 6, e633.	0.8	2
16	Belatacept and CD28 Costimulation Blockade: Preventing and Reducing Alloantibodies over the Long Term. Current Transplantation Reports, 2019, 6, 277-284.	0.9	10
17	Kinetics of antibody response to influenza vaccination in renal transplant recipients. Transplant Immunology, 2019, 53, 51-60.	0.6	20
18	Patient Navigators in Transplantation—Where Do We Go From Here?. Transplantation, 2019, 103, 1076-1077.	0.5	4

#	Article	IF	Citations
19	Corticosteroids and methotrexate as adjuvants to costimulation blockade in nonâ€human primate renal transplantation. Clinical Transplantation, 2019, 33, e13568.	0.8	1
20	Long-term survival of pig-to-rhesus macaque renal xenografts is dependent on CD4 T cell depletion. American Journal of Transplantation, 2019, 19, 2174-2185.	2.6	136
21	Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation. American Journal of Transplantation, 2019, 19, 2342-2349.	2.6	23
22	Effect of the iChoose Kidney decision aid in improving knowledge about treatment options among transplant candidates: A randomized controlled trial. American Journal of Transplantation, 2018, 18, 1954-1965.	2.6	56
23	Outcomes at 7Âyears postâ€transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in <scp>BENEFIT</scp> and <scp>BENEFIT</scp> â€ <scp>EXT</scp> . Clinical Transplantation, 2018, 32, e13225.	0.8	8
24	Emergency department use among kidney transplant recipients in the United States. American Journal of Transplantation, 2018, 18, 868-880.	2.6	13
25	The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms. American Journal of the Medical Sciences, 2018, 356, 433-440.	0.4	17
26	CD122 signaling in CD8+ memory T cells drives costimulation-independent rejection. Journal of Clinical Investigation, 2018, 128, 4557-4572.	3.9	40
27	Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. American Journal of Transplantation, 2017, 17, 2922-2936.	2.6	86
28	Interruption of OX40L signaling prevents costimulation blockade–resistant allograft rejection. JCI Insight, 2017, 2, e90317.	2.3	11
29	Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway. Journal of Immunology, 2016, 197, 2045-2050.	0.4	83
30	Enhanced Requirement for TNFR2 in Graft Rejection Mediated by Low-Affinity Memory CD8+ T Cells during Heterologous Immunity. Journal of Immunology, 2016, 197, 2009-2015.	0.4	7
31	Belatacept and Long-Term Outcomes in Kidney Transplantation. New England Journal of Medicine, 2016, 374, 333-343.	13.9	593
32	Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity. Journal of Immunology, 2016, 196, 2838-2846.	0.4	41
33	Preâ€transplant antibody screening and antiâ€CD154 costimulation blockade promote longâ€term xenograft survival in a pigâ€toâ€primate kidney transplant model. Xenotransplantation, 2015, 22, 221-230.	1.6	178
34	Ebola Virus Disease: Experience and Decision Making for the First Patients outside of Africa. PLoS Medicine, 2015, 12, e1001857.	3.9	20
35	Belatacept. , 2014, , 314-319.		3
36	InÂVivo T Cell Costimulation Blockade with Abatacept forÂAcute Graft-versus-Host Disease Prevention: A First-in-Disease Trial. Biology of Blood and Marrow Transplantation, 2013, 19, 1638-1649.	2.0	96

#	Article	IF	Citations
37	Heterologous Immunity Triggered by a Single, Latent Virus in Mus musculus: Combined Costimulationand Adhesion-Blockade Decrease Rejection. PLoS ONE, 2013, 8, e71221.	1.1	14
38	The Impact of Renal Function on Outcomes of Bariatric Surgery. Journal of the American Society of Nephrology: JASN, 2012, 23, 885-894.	3.0	93
39	Nondepleting Anti-CD40-Based Therapy Prolongs Allograft Survival in Nonhuman Primates. American Journal of Transplantation, 2012, 12, 126-135.	2.6	65
40	CD40 Blockade Combines with CTLA4Ig and Sirolimus to Produce Mixed Chimerism in an MHC-Defined Rhesus Macaque Transplant Model. American Journal of Transplantation, 2012, 12, 115-125.	2.6	54
41	Integrin Antagonists Prevent Costimulatory Blockade-Resistant Transplant Rejection by CD8+ Memory T Cells. American Journal of Transplantation, 2012, 12, 69-80.	2.6	72
42	Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients. American Journal of Transplantation, 2012, 12, 210-217.	2.6	280
43	Cumulative Exposure to Gamma Interferon-Dependent Chemokines CXCL9 and CXCL10 Correlates with Worse Outcome After Lung Transplant. American Journal of Transplantation, 2012, 12, 438-446.	2.6	24
44	Nonhuman Primate Transplant Models Finally Evolve: Detailed Immunogenetic Analysis Creates New Models and Strengthens the Old. American Journal of Transplantation, 2012, 12, 812-819.	2.6	25
45	Regulatory T Cells Exhibit Decreased Proliferation but Enhanced Suppression After Pulsing With Sirolimus. American Journal of Transplantation, 2012, 12, 1441-1457.	2.6	46
46	CTLA4Ig Prevents Alloantibody Formation Following Nonhuman Primate Islet Transplantation Using the CD40-Specific Antibody 3A8. American Journal of Transplantation, 2012, 12, 1918-1923.	2.6	44
47	Alternative Immunomodulatory Strategies for Xenotransplantation: CD40/154 Pathway-Sparing Regimens Promote Xenograft Survival. American Journal of Transplantation, 2012, 12, 1765-1775.	2.6	70
48	Evidence for Kidney Rejection After Combined Bone Marrow and Renal Transplantation Despite Ongoing Whole-Blood Chimerism in Rhesus Macaques. American Journal of Transplantation, 2012, 12, 1755-1764.	2.6	21
49	A Novel Monoclonal Antibody to CD40 Prolongs Islet Allograft Survival. American Journal of Transplantation, 2012, 12, 2079-2087.	2.6	74
50	Immunogenetic Management Software: a new tool for visualization and analysis of complex immunogenetic datasets. Immunogenetics, 2012, 64, 329-336.	1.2	8
51	CD28 blockade induces division-dependent downregulation of interleukin-2 receptor alpha. Transplant Immunology, 2011, 24, 94-99.	0.6	3
52	Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies). Transplantation, 2011, 91, 976-983.	0.5	148
53	Glial Cell Line–Derived Neurotrophic Factor Enhances Human Islet Posttransplantation Survival. Transplantation, 2011, 92, 745-751.	0.5	13
54	LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4lg to inhibit effector function. Blood, 2011, 118, 5851-5861.	0.6	34

#	Article	IF	CITATIONS
55	Selective Targeting of Human Alloresponsive CD8+ Effector Memory T Cells Based on CD2 Expression. American Journal of Transplantation, 2011, 11, 22-33.	2.6	118
56	Sirolimus Enhances the Magnitude and Quality of Viral-Specific CD8+ T-Cell Responses to Vaccinia Virus Vaccination in Rhesus Macaques. American Journal of Transplantation, 2011, 11, 613-618.	2.6	94
57	CD40-Specific Costimulation Blockade Enhances Neonatal Porcine Islet Survival in Nonhuman Primates. American Journal of Transplantation, 2011, 11, 947-957.	2.6	137
58	Miles to Go…. American Journal of Transplantation, 2011, 11, 1119-1120.	2.6	16
59	Islet Xenotransplantation Using Gal-Deficient Neonatal Donors Improves Engraftment and Function. American Journal of Transplantation, 2011, 11, 2593-2602.	2,6	136
60	Cumulative Exposure to CD8+ Granzyme Bhi T Cells Is Associated with Reduced Lung Function Early after Lung Transplantation. Transplantation Proceedings, 2011, 43, 3892-3898.	0.3	6
61	Regulatory T cells in lung transplantationâ€"an emerging concept. Seminars in Immunopathology, 2011, 33, 117-127.	2.8	29
62	Integrin antagonists for transplant immunosuppression: panacea or peril?. Immunotherapy, 2011, 3, 305-307.	1.0	13
63	Limiting the Amount and Duration of Antigen Exposure during Priming Increases Memory T Cell Requirement for Costimulation during Recall. Journal of Immunology, 2011, 186, 2033-2041.	0.4	32
64	Antigen-specific induced Foxp3 ⁺ regulatory T cells are generated following CD40/CD154 blockade. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20701-20706.	3.3	82
65	Transplantation Tolerance: Memories That Haunt Us. Science Translational Medicine, 2011, 3, 86ps22.	5.8	12
66	High-Frequency Alloreactive T Cells Augment Effector Function of Low-Frequency CD8+ T-Cell Responses Under CD28/CD154 Blockade. Transplantation, 2010, 89, 1208-1217.	0.5	7
67	Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies. Transplantation, 2010, 90, 1528-1535.	0.5	156
68	An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients. Transplantation, 2010, 90, 1521-1527.	0.5	108
69	Overcoming the memory barrier in tolerance induction: molecular mimicry and functional heterogeneity among pathogen-specific T-cell populations. Current Opinion in Organ Transplantation, 2010, 15, 405-410.	0.8	43
70	GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28â ⁻ CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. Blood, 2010, 116, 5403-5418.	0.6	67
71	A Phase III Study of Belataceptâ€based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study). American Journal of Transplantation, 2010, 10, 535-546.	2.6	838
72	Experience with a Novel Efalizumabâ€Based Immunosuppressive Regimen to Facilitate Single Donor Islet Cell Transplantation. American Journal of Transplantation, 2010, 10, 2082-2091.	2.6	98

#	Article	IF	Citations
73	An MHC-Defined Primate Model Reveals Significant Rejection of Bone Marrow After Mixed Chimerism Induction Despite Full MHC Matching. American Journal of Transplantation, 2010, 10, 2396-2409.	2.6	50
74	Decreased incidence of NSF in patients on dialysis after changing gadolinium contrastâ€enhanced MRI protocols. Journal of Magnetic Resonance Imaging, 2010, 31, 440-446.	1.9	102
75	LFA-1–specific therapy prolongs allograft survival in rhesus macaques. Journal of Clinical Investigation, 2010, 120, 4520-4531.	3.9	106
76	Five-Year Safety and Efficacy of Belatacept in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2010, 21, 1587-1596.	3.0	177
77	Transient CD86 Expression on Hepatitis C Virus-Specific CD8+ T Cells in Acute Infection Is Linked to Sufficient IL-2 Signaling. Journal of Immunology, 2010, 184, 2410-2422.	0.4	18
78	Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses. Journal of Immunology, 2010, 185, 2004-2008.	0.4	106
79	Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation. Journal of Experimental Medicine, 2010, 207, 2355-2367.	4.2	33
80	SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM A POOLED ANALYSIS OF PHASE II AND PHASE III STUDIES. Transplantation, 2010, 90, 156.	0.5	3
81	BELATACEPT VS CYCLOSPORINE IN ECD KIDNEY TRANSPLANTS: TWO-YEAR OUTCOMES FROM THE BENEFIT-EXT STUDY. Transplantation, 2010, 90, 157.	0.5	5
82	Surgical Correction of Gastroesophageal Reflux in Lung Transplant Patients Is Associated With Decreased Effector CD8 Cells in Lung Lavages. Chest, 2010, 138, 937-943.	0.4	12
83	IFN- \hat{l}^3 Dictates Allograft Fate via Opposing Effects on the Graft and on Recipient CD8 T Cell Responses. Journal of Immunology, 2009, 182, 225-233.	0.4	21
84	Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation. Journal of Immunology, 2009, 183, 1625-1635.	0.4	73
85	A novel calcineurin inhibitor– and sirolimus-free anti-LFA-1-based therapy enhances allogeneic islet survival and function in nonhuman primates. Journal of the American College of Surgeons, 2009, 209, S56.	0.2	0
86	mTOR regulates memory CD8 T-cell differentiation. Nature, 2009, 460, 108-112.	13.7	1,346
87	Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nature Medicine, 2009, 15, 746-749.	15.2	183
88	Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunological Reviews, 2009, 229, 294-306.	2.8	119
89	Successful outcome after early combined liver and <i>en bloc</i> ê€kidney transplant in an infant with primary hyperoxaluria type 1: A case report. Pediatric Transplantation, 2009, 13, 940-942.	0.5	5
90	Prevention Of Acute GvHD During Haplo-BMT: Evaluating The Efficacy Of T-Cell Costimulation Blockade Using A Novel Rhesus Macaque Transplant Model. Biology of Blood and Marrow Transplantation, 2009, 15, 114-115.	2.0	2

#	Article	IF	Citations
91	Donor-Reactive T-Cell Stimulation History and Precursor Frequency: Barriers to Tolerance Induction. Transplantation, 2009, 87, S69-S74.	0.5	40
92	Dynamics of Human Regulatory T Cells in Lung Lavages of Lung Transplant Recipients. Transplantation, 2009, 88, 521-527.	0.5	29
93	Kidney transplantation: Structural and functional evaluation using MR Nephroâ€Urography. Journal of Magnetic Resonance Imaging, 2008, 28, 805-822.	1.9	29
94	Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature, 2008, 453, 667-671.	13.7	959
95	Immune responsiveness and protective immunity after transplantation. Transplant International, 2008, 21, 293-303.	0.8	64
96	Measuring symptom experience of side-effects of immunosuppressive drugs: the Modified Transplant Symptom Occurrence and Distress Scale. Transplant International, 2008, 21, 764-773.	0.8	66
97	Immunosuppressive protocols for pig-to-human islet transplantation: lessons from pre-clinical non-human primate models. Xenotransplantation, 2008, 15, 107-111.	1.6	8
98	Expanded Nonhuman Primate Tregs Exhibit a Unique Gene Expression Signature and Potently Downregulate Alloimmune Responses. American Journal of Transplantation, 2008, 8, 2252-2264.	2.6	25
99	Glial Cell Line-Derived Neurotrophic Factor Increases Î ² -Cell Mass and Improves Glucose Tolerance. Gastroenterology, 2008, 134, 727-737.	0.6	39
100	CD28/CD154 Blockade Prevents Autoimmune Diabetes by Inducing Nondeletional Tolerance After Effector T-Cell Inhibition and Regulatory T-Cell Expansion. Diabetes, 2008, 57, 2672-2683.	0.3	32
101	A Critical Precursor Frequency of Donor-Reactive CD4+ T Cell Help Is Required for CD8+ T Cell-Mediated CD28/CD154-Independent Rejection. Journal of Immunology, 2008, 180, 7203-7211.	0.4	27
102	PD-1-Dependent Mechanisms Maintain Peripheral Tolerance of Donor-Reactive CD8+ T Cells to Transplanted Tissue. Journal of Immunology, 2008, 181, 5313-5322.	0.4	48
103	Expansion of Effector Memory TCR \hat{V}^2 4+CD8+ T Cells Is Associated with Latent Infection-Mediated Resistance to Transplantation Tolerance. Journal of Immunology, 2008, 180, 3190-3200.	0.4	31
104	INFLUENCE OF DONOR TYPE ON ELDERLY KIDNEY TRANSPLANT SURVIVAL AND ALLOGRAFT FUNCTION. Transplantation, 2008, 86, 116.	0.5	0
105	Belatacept and Basiliximab Diminish Human Antiporcine Xenoreactivity and Synergize to Inhibit Alloimmunity. Transplantation, 2008, 85, 118-124.	0.5	11
106	Protective Immunity in Transplant Recipients. FASEB Journal, 2008, 22, 532-532.	0.2	0
107	Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15430-15435.	3.3	206
108	Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. Journal of Experimental Medicine, 2007, 204, 299-309.	4.2	119

#	Article	IF	CITATIONS
109	Fully MHC-Disparate Mixed Hemopoietic Chimeras Show Specific Defects in the Control of Chronic Viral Infections. Journal of Immunology, 2007, 179, 2616-2626.	0.4	17
110	Role of CD28 in fatal autoimmune disorder in scurfy mice. Blood, 2007, 110, 1199-1206.	0.6	33
111	Infusion of Stably Immature Monocyte-Derived Dendritic Cells Plus CTLA4Ig Modulates Alloimmune Reactivity in Rhesus Macaques. Transplantation, 2007, 84, 196-206.	0.5	51
112	Transplantation Tolerance. Seminars in Nephrology, 2007, 27, 487-497.	0.6	7
113	(2) Targeting the T-cell costimulation pathways allows long-term survival of neonatal porcine islets in diabetic non-human primates. Xenotransplantation, 2007, 14, 178-179.	1.6	1
114	Induction of Chimerism in Rhesus Macaques through Stem Cell Transplant and Costimulation Blockade-Based Immunosuppression. American Journal of Transplantation, 2007, 7, 320-335.	2.6	65
115	Alloimmunity: No Toll Exemption. American Journal of Transplantation, 2007, 7, 3-4.	2.6	3
116	Antigenic Disparity Impacts Outcome of Agonism but Not Blockade of Costimulatory Pathways in Experimental Transplant Models. American Journal of Transplantation, 2007, 7, 1471-1481.	2.6	4
117	NK Cells Rapidly Reject Allogeneic Bone Marrow in the Spleen Through a Perforin―and Ly49Dâ€Dependent, but NKG2D―ndependent Mechanism. American Journal of Transplantation, 2007, 7, 1884-1896.	2.6	40
118	Engraftment of Adult Porcine Islet Xenografts in Diabetic Nonhuman Primates Through Targeting of Costimulation Pathways. American Journal of Transplantation, 2007, 7, 2260-2268.	2.6	87
119	F.142. Inhibition of T-Cell Activation By CD28 and CD40L Blockade Is Influenced By T-Cell Precursor Frequency. Clinical Immunology, 2006, 119, S100-S101.	1.4	0
120	Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 1239-1249.	2.0	11
121	Immunosuppressive and Trafficking Properties of Donor Splenic and Bone Marrow Dendritic Cells. Transplantation, 2006, 81, 455-462.	0.5	15
122	Tolerance Assays: Measuring the Unknown. Transplantation, 2006, 81, 1503-1509.	0.5	42
123	Transplant Tolerance: Converging on a Moving Target. Transplantation, 2006, 81, 1-6.	0.5	32
124	Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nature Medicine, 2006, 12, 304-306.	15.2	439
125	NK Cells Mediate Costimulation Blockade-Resistant Rejection of Allogeneic Stem Cells During Nonmyeloablative Transplantation. American Journal of Transplantation, 2006, 6, 292-304.	2.6	74
126	A New Look at Blockade of T-cell Costimulation: A Therapeutic Strategy for Long-term Maintenance Immunosuppression. American Journal of Transplantation, 2006, 6, 876-883.	2.6	135

#	Article	IF	Citations
127	Transplant Tolerance in Non-Human Primates: Progress, Current Challenges and Unmet Needs. American Journal of Transplantation, 2006, 6, 884-893.	2.6	75
128	A Mouse Model for Polyomavirus-Associated Nephropathy of Kidney Transplants. American Journal of Transplantation, 2006, 6, 913-922.	2.6	39
129	Toward Transplantation Tolerance: A Large Step on a Long Road. American Journal of Transplantation, 2006, 6, 1989-1990.	2.6	7
130	Transplanting the Highly Sensitized Patient: The Emory Algorithm. American Journal of Transplantation, 2006, 6, 2307-2315.	2.6	192
131	F.141. A Role for PD-1 in Maintaining Peripheral Tolerance to An Allogeneic Skin Graft. Clinical Immunology, 2006, 119, S100.	1.4	0
132	OR.96. Long-Term Survival of Neonatal Porcine Islet Xenografts in Diabetic Non-Human Primates By Targeting Costimulation Pathways. Clinical Immunology, 2006, 119, S40.	1.4	0
133	Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. Journal of Experimental Medicine, 2006, 203, 2263-2269.	4.2	169
134	Costimulation Requirements for Antiviral CD8+ T Cells Differ for Acute and Persistent Phases of Polyoma Virus Infection. Journal of Immunology, 2006, 176, 1814-1824.	0.4	33
135	Patients, Pathogens, and Protective Immunity: The Relevance of Virus-Induced Alloreactivity in Transplantation. Journal of Immunology, 2006, 176, 2691-2696.	0.4	28
136	Establishment of Chimerism in Rhesus Macaques through Nonmyeloablative Hematopoietic Stem Cell Transplant and Costimulation Blockade-Based Immunosuppression Blood, 2006, 108, 3202-3202.	0.6	0
137	Apoptotic Cells Break Tolerance Induced by CD40-CD40L Blockade Blood, 2006, 108, 3221-3221.	0.6	0
138	Induction of Chimerism and Tolerance Using Freshly Purified or Cultured Hematopoietic Stem Cells in Nonmyeloablated Mice., 2005, 109, 459-468.		5
139	Enhanced immunosuppression induced by targeted mutation of cytotoxic T lymphocyte antigen 4-immunoglobulin. Current Opinion in Organ Transplantation, 2005, 10, 265-269.	0.8	4
140	Rational Development of LEA29Y (belatacept), a Highâ€Affinity Variant of CTLA4â€ig with Potent Immunosuppressive Properties. American Journal of Transplantation, 2005, 5, 443-453.	2.6	655
141	Late Priming and Variability of Epitope-Specific CD8+ T Cell Responses during a Persistent Virus Infection. Journal of Immunology, 2005, 174, 7950-7960.	0.4	70
142	Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival. Journal of Immunology, 2005, 174, 542-550.	0.4	177
143	Impaired Recall of CD8 Memory T Cells in Immunologically Privileged Tissue. Journal of Immunology, 2005, 174, 1165-1170.	0.4	57
144	NK cell alloreactivity is an important mediator of costimulation-blockade-resistant rejection during allogeneic transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 36-37.	2.0	0

#	Article	IF	Citations
145	Costimulation Blockade with Belatacept in Renal Transplantation. New England Journal of Medicine, 2005, 353, 770-781.	13.9	827
146	NK Cells Efficiently Prevent Engraftment of Donor Stem Cells after Tolerigenic Bone Marrow Transplantation Blood, 2005, 106, 3025-3025.	0.6	1
147	Berkeley Sickle Mice Demonstrate CD8- and NK1.1-Dependent Increased Rejection of Allogeneic Hematopoietic Stem Cell Transplants Blood, 2005, 106, 2332-2332.	0.6	0
148	Multiple Combination Therapies Involving Blockade of ICOS/B7RP-1 Costimulation Facilitate Long-Term Islet Allograft Survival. American Journal of Transplantation, 2004, 4, 526-536.	2.6	68
149	Ability of donor splenocytes with costimulation blockade to induce mixed hematopoietic chimerism and transplantation tolerance. Transplantation Proceedings, 2004, 36, 2423-2424.	0.3	2
150	THE CD134/CD134L PATHWAY IS CRITICAL IN CD8-MEDIATED COSTIMULATION BLOCKADE RESISTANT REJECTION Transplantation, 2004, 78, 181.	0.5	3
151	CO-STIMULATION BLOCKADE WITH LEA29Y IN A CALCINEURIN INHIBITOR FREE MAINTENANCE REGIMEN IN RENAL TRANSPLANT: 6-MONTH EFFICACY AND SAFETY. Transplantation, 2004, 78, 264-265.	0.5	9
152	Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. Journal of Clinical Investigation, 2004, 113, 836-845.	3.9	32
153	Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replication. Journal of Clinical Investigation, 2004, 113, 836-845.	3.9	41
154	Role of 4-1BB in Allograft Rejection Mediated by CD8+ T Cells. American Journal of Transplantation, 2003, 3, 543-551.	2.6	64
155	Long-Term Survival of Intestinal Allografts Induced by Costimulation Blockade, Busulfan and Donor Bone Marrow Infusion. American Journal of Transplantation, 2003, 3, 1091-1098.	2.6	34
156	Conventional Immunosuppression is Compatible with Costimulation Blockade-Based, Mixed Chimerism Tolerance Induction. American Journal of Transplantation, 2003, 3, 895-901.	2.6	22
157	Simultaneous Pancreas-Kidney Transplantation Utilizing a Common Arterial Conduit: Early Experience and Potential Applications. American Journal of Transplantation, 2003, 3, 1440-1443.	2.6	18
158	Allogeneic Parenchymal and Hematopoietic Tissues Differ in Their Ability to Induce Deletion of Donor-Reactive T Cells. American Journal of Transplantation, 2003, 3, 1520-1530.	2.6	4
159	Heterologous immunity: an overlooked barrier to tolerance. Immunological Reviews, 2003, 196, 147-160.	2.8	214
160	Primary and Secondary Immunocompetence in Mixed Allogeneic Chimeras. Journal of Immunology, 2003, 170, 2382-2389.	0.4	26
161	Targeting the ICOS-B7h Costimulatory Pathway Synergizes with Rapamycin to Regulate Alloresponses in Islet Transplantation. Transplantation, 2003, 76, S51.	0.5	0
162	COMBINED CD40/CD28 BLOCKADE SYNERGIZES TO PROMOTE ISLET ALLOGRAFT SURVIVAL IN A NONHUMAN PRIMATE MODEL. Transplantation, 2003, 76, S31.	0.5	0

#	Article	IF	Citations
163	Induction of operational tolerance to discordant dopaminergic porcine xenografts1. Transplantation, 2003, 75, 1448-1454.	0.5	24
164	Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood, 2003, 102, 4582-4593.	0.6	56
165	Intravital microscopy identifies selectins that regulate T cell traffic into allografts. Journal of Clinical Investigation, 2003, 112, 1714-1723.	3.9	21
166	Heterologous immunity provides a potent barrier to transplantation tolerance. Journal of Clinical Investigation, 2003, 111, 1887-1895.	3.9	283
167	Heterologous immunity provides a potent barrier to transplantation tolerance. Journal of Clinical Investigation, 2003, 111, 1887-1895.	3.9	535
168	The Role of the IL-2 Pathway in Costimulation Blockade-Resistant Rejection of Allografts. Journal of Immunology, 2002, 168, 1123-1130.	0.4	54
169	Cutting Edge: Persistent Viral Infection Prevents Tolerance Induction and Escapes Immune Control Following CD28/CD40 Blockade-Based Regimen. Journal of Immunology, 2002, 169, 5387-5391.	0.4	98
170	Dynamic Regulation of T Cell Immunity by CD43. Journal of Immunology, 2002, 168, 6022-6031.	0.4	108
171	Calcineurin Inhibitor-Free CD28 Blockade-Based Protocol Protects Allogeneic Islets in Nonhuman Primates. Diabetes, 2002, 51, 265-270.	0.3	165
172	Prevention of Chronic Rejection in Murine Cardiac Allografts: A Comparison of Chimerism- and Nonchimerism-Inducing Costimulation Blockade-Based Tolerance Induction Regimens. Journal of Immunology, 2002, 169, 2677-2684.	0.4	54
173	Anti-CD40 therapy extends renal allograft survival in rhesus macaques1. Transplantation, 2002, 74, 933-940.	0.5	147
174	Costimulation blockade and tolerance. Current Opinion in Organ Transplantation, 2002, 7, 7-12.	0.8	2
175	Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice1. Transplantation, 2002, 74, 35-41.	0.5	29
176	A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex–mismatched bone marrow transplantation. Blood, 2002, 99, 1840-1849.	0.6	71
177	CTLA4lg combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transplant Immunology, 2002, 10, 55-61.	0.6	39
178	SVR Angiosarcomas can be Rejected by CD4 Costimulation Dependent and CD8 Costimulation Independent Pathways. Molecular Medicine, 2002, 8, 551-558.	1.9	8
179	The Role of TNF Receptor and TNF Superfamily Molecules in Organ Transplantation. American Journal of Transplantation, 2002, 2, 12-18.	2.6	51
180	Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection of discordant neural xenografts in mice lacking CD40L. Xenotransplantation, 2002, 9, 68-76.	1.6	25

#	Article	IF	CITATIONS
181	CTLA4IG INDUCES LONG-TERM GRAFT SURVIVAL OF ALLOGENEIC SKIN GRAFTS AND TOTALLY INHIBITS T-CELL PROLIFERATION IN LFA-1???DEFICIENT MICE. Transplantation, 2002, 73, 293-297.	0.5	25
182	Aggressive skin allograft rejection in CD28 \hat{a} '/ \hat{a} ' mice independent of the CD40/CD40L costimulatory pathway. Transplant Immunology, 2001, 9, 13-17.	0.6	10
183	Innate Immune Responses to Transplants. Immunity, 2001, 14, 369-376.	6.6	95
184	Blockade of the CD40 pathway fails to prevent CD8 T cell-mediated intestinal allograft rejection. Transplantation Proceedings, 2001, 33, 418-420.	0.3	7
185	FasL IS IMPORTANT IN COSTIMULATION BLOCKADE-RESISTANT SKIN GRAFT REJECTION. Transplantation, 2001, 71, 537-543.	0.5	7
186	GENE EXPRESSION ANALYSIS IN HUMAN RENAL ALLOGRAFT BIOPSY SAMPLES USING HIGH-DENSITY OLIGOARRAY TECHNOLOGY1. Transplantation, 2001, 72, 948-953.	0.5	108
187	CD8 T CELL-MEDIATED REJECTION OF INTESTINAL ALLOGRAFTS IS RESISTANT TO INHIBITION OF THE CD40/CD154 COSTIMULATORY PATHWAY. Transplantation, 2001, 71, 1351-1354.	0.5	47
188	Costimulation Blockade, Busulfan, and Bone Marrow Promote Titratable Macrochimerism, Induce Transplantation Tolerance, and Correct Genetic Hemoglobinopathies with Minimal Myelosuppression. Journal of Immunology, 2001, 167, 1103-1111.	0.4	148
189	Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory. Journal of Immunology, 2001, 167, 5565-5573.	0.4	180
190	Characterization of Virus-Mediated Inhibition of Mixed Chimerism and Allospecific Tolerance. Journal of Immunology, 2001, 167, 4987-4995.	0.4	86
191	Conventional immunosuppression and co-stimulation blockade. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 703-705.	1.8	17
192	ANALYSIS OF THE CD40 AND CD28 PATHWAYS ON ALLOIMMUNE RESPONSES BY CD4+ T CELLS IN VIVO1. Transplantation, 2001, 72, 1286-1292.	0.5	17
193	ADMINISTRATION OF REPEATED DOSES OF ANTI-CD40L AND DONOR BONE MARROW LEADS TO HEMATOPOIETIC CHIMERISM AND DONOR SPECIFIC TOLERANCE WITHOUT CYTOREDUCTIVE CONDITIONING Transplantation, 2000, 69, S240.	0.5	2
194	ROLE OF CD40L IN THE INITIATION, AMPLIFICATION, AND EFFECTOR PHASE OF ALLOIMMUNE RESPONSES Transplantation, 2000, 69, S131.	0.5	0
195	HEMATOPOIETIC CHIMERISM IN THE PRESENCE OF CD40 AND CD28 BLOCKADE LEADS TO PERIPHERAL DELETION OF DONOR REACTIVE T CELLS AND DEVELOPMENT OF DONOR SPECIFIC TRANSPLANTATION TOLERANCE Transplantation, 2000, 69, S240.	0.5	1
196	PROLONGATION OF RENAL ALLOGRAFT SURVIVAL BY A CHIMERIC ANTI-HUMAN CD40 MONOCLONAL ANTIBODY IN NONHUMAN PRIMATES Transplantation, 2000, 69, S123.	0.5	2
197	PROLONGATION OF RENAL ALLOGRAFT SURVIVAL WITH BLOCKADE OF THE CD28 PATHWAY USING A NOVEL MUTANT CTLA4-IG FUSION PROTEIN IN NON-HUMAN PRIMATES Transplantation, 2000, 69, S123.	0.5	3
198	FAS LIGAND PLAYS A CRUCIAL ROLE IN COSTIMULATION BLOCKADE RESISTANT REJECTION Transplantation, 2000, 69, S398.	0.5	0

#	Article	IF	CITATIONS
199	Interpreting murine tolerance experiments. Current Opinion in Organ Transplantation, 2000, 5, 103-107.	0.8	3
200	Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation. Clinical Transplantation, 2000, 14, 413-420.	0.8	26
201	Vigorous Allograft Rejection in the Absence of Danger. Journal of Immunology, 2000, 164, 3065-3071.	0.4	73
202	Cutting Edge: Administration of Anti-CD40 Ligand and Donor Bone Marrow Leads to Hemopoietic Chimerism and Donor-Specific Tolerance Without Cytoreductive Conditioning. Journal of Immunology, 2000, 165, 1-4.	0.4	239
203	4-1BB Costimulation Is Required for Protective Anti-Viral Immunity After Peptide Vaccination. Journal of Immunology, 2000, 164, 2320-2325.	0.4	126
204	Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts. Journal of Immunology, 2000, 165, 6849-6857.	0.4	128
205	The role of CD40L in T cell-dependent nitric oxide production by murine macrophages. Transplant Immunology, 2000, 8, 195-202.	0.6	20
206	TRANSPLANTATION OF THE BONE MARROW MICROENVIRONMENT LEADS TO HEMATOPOIETIC CHIMERISM WITHOUT CYTOREDUCTIVE CONDITIONING1. Transplantation, 2000, 69, 2491-2496.	0.5	36
207	Asialo GM1+ CD8+ T cells play a critical role in costimulation blockade–resistant allograft rejection. Journal of Clinical Investigation, 1999, 104, 1715-1722.	3.9	329
208	PROLONGED ACCEPTANCE OF CONCORDANT AND DISCORDANT XENOGRAFTS WITH COMBINED CD40 AND CD28 PATHWAY BLOCKADE1. Transplantation, 1998, 65, 1422-1428.	0.5	113
209	4-1BB Costimulatory Signals Preferentially Induce CD8+ Tâ€,Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses. Journal of Experimental Medicine, 1997, 186, 47-55.	4.2	710
210	Microchimerism and rejection in clinical transplantation. Lancet, The, 1997, 349, 1358-1360.	6.3	147
211	The CD40 pathway in allograft rejection, acceptance, and tolerance. Current Opinion in Immunology, 1997, 9, 641-647.	2.4	176
212	ANALYSIS OF THE B7 COSTIMULATORY PATHWAY IN ALLOGRAFT REJECTION1. Transplantation, 1997, 63, 1463-1469.	0.5	77
213	Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature, 1996, 381, 434-438.	13.7	1,430
214	CD40-gp39 INTERACTIONS PLAY A CRITICAL ROLE DURING ALLOGRAFT REJECTION. Transplantation, 1996, 61, 4-9.	0.5	308
215	CTLA4-Ig PLUS BONE MARROW INDUCES LONG-TERM ALLOGRAFT SURVIVAL AND DONOR-SPECIFIC UNRESPONSIVENESS IN THE MURINE MODEL. Transplantation, 1996, 61, 997-1004.	0.5	115
216	FAS-MEDIATED CYTOTOXICITY AN IMMUNOEFFECTOR OR IMMUNOREGULATORY PATHWAY IN T CELL-MEDIATED IMMUNE RESPONSES?. Transplantation, 1995, 60, 221-224.	0.5	82

#	Article	IF	Citations
217	DELAYED URINARY BLADDER LEAK AFTER COMBINED KIDNEY-PANCREAS TRANSPLANTATION ASSOCIATION WITH PENILE PROSTHESIS IMPLANTATION. Transplantation, 1995, 60, 624.	0.5	4
218	IDENTIFICATION OF DONOR-DERIVED DENDRITIC CELL PROGENITORS IN BONE MARROW OF SPONTANEOUSLY TOLERANT LIVER ALLOGRAFT RECIPIENTS1,2. Transplantation, 1995, 60, 1555-1559.	0.5	47
219	Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1 Journal of Experimental Medicine, 1995, 181, 2237-2247.	4.2	451
220	Prolongation of Murine Cardiac Allograft Survival by Microspheres Containing TNFÎ \pm and IL1-Î 2 Neutralizing Antibodies. Journal of Drug Targeting, 1995, 3, 311-315.	2.1	19
221	SYSTEMIC LIPOPOLYSACCHARIDE RECRUITS DENDRITIC CELL PROGENITORS TO NONLYMPHOID TISSUES. Transplantation, 1995, 59, 1319-1324.	0.5	40
222	TRANSPLANTATION TOLERANCE INDUCED BY CTLA4-lg1. Transplantation, 1994, 57, 1701-1705.	0.5	277
223	Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations Journal of Experimental Medicine, 1992, 176, 1215-1220.	4.2	284
224	INDUCTION OF TRANSPLANTATION TOLERANCE IN ADULTS USING DONOR ANTIGEN AND ANTI-CD4 MONOCLONAL ANTIBODY. Transplantation, 1992, 54, 475-482.	0.5	145
225	Cytokine Gene Expression: Analysis using Northern Blotting, Polymerase Chain Reaction and in situ Hybridization. Immunological Reviews, 1991, 119, 163-179.	2.8	109
226	Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction Journal of Experimental Medicine, 1991, 174, 493-496.	4.2	271
227	MIGRATION PATTERNS OF DENDRITIC LEUKOCYTES. Transplantation, 1990, 49, 1-7.	0.5	126
228	FAILURE OF MATURE DENDRITIC CELLS OF THE HOST TO MIGRATE FROM THE BLOOD INTO CARDIAC OR SKIN ALLOGRAFTS. Transplantation, 1990, 50, 294-300.	0.5	27
229	The Role of Graft-derived Dendritic Leukocytes in the Rejection of Vascularized Organ Allografts. Annals of Surgery, 1990, 212, 308-317.	2.1	78
230	Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection Journal of Experimental Medicine, 1990, 171, 307-314.	4.2	539
231	Migration and maturation of Langerhans cells in skin transplants and explants Journal of Experimental Medicine, 1990, 172, 1483-1493.	4.2	616